Federal Appeals Court Restricts Mail-Order Access to Abortion Pill Mifepristone
The 5th U.S. Circuit Court of Appeals has ruled that mifepristone must be dispensed in person at clinics, blocking its distribution by mail.
A federal appeals court has mandated that mifepristone, a widely used abortion pill, be dispensed exclusively in person at clinics, effectively prohibiting its distribution by mail. The unanimous decision by the 5th U.S. Circuit Court of Appeals overturns previous FDA regulations that permitted telehealth prescriptions and mail delivery of the medication.
The ruling stems from a lawsuit filed by Louisiana Attorney General Liz Murrill, who argued that mailing mifepristone undermines the state's abortion ban. Judge Kyle Duncan, writing for the court, stated that the FDA's actions "cancel Louisiana's ban on medical abortions and undermine its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person.'"
Mifepristone, approved by the FDA in 2000, is commonly used in combination with misoprostol to terminate early pregnancies. The appeals court's decision affects all states, including those without abortion restrictions, and is expected to be appealed to the U.S. Supreme Court.
In response, Danco Laboratories, a manufacturer of mifepristone, has petitioned the Supreme Court to block the appellate court's ruling, citing concerns over "immediate confusion and upheaval into highly time-sensitive medical decisions."
This development marks the most significant federal restriction on abortion access since the Supreme Court's 2022 decision overturning Roe v. Wade. Legal experts anticipate that the case could influence abortion policy debates ahead of the upcoming midterm elections.